Shimei Fu

Sep 16, 2024 | onlinelibrary.wiley.com | Xiaxia Chen |Wei Zhang |Lan Luo |Shimei Fu

1 INTRODUCTION More than 50% of patients are diagnosed with stage IV NSCLC,1-3 and the 5-year overall survival (OS) of NSCLC is still only 19%.4 IV NSCLC patients with EGFR gene-sensitive mutations, ALK gene or ROS1 gene fusion can be treated with first-line targeted drugs.5-8 Immunotherapy drugs such as pembrolizumab monoclonal antibodies can be used for patients with PD-L1 TPS ≥1%.9 Stage IV NSCLC patients without a driver gene is mainly treated by platinum-based systemic chemotherapy, and...